ChemoMetec Statistics

Total Valuation

ChemoMetec has a market cap or net worth of GBP 1.11 billion. The enterprise value is 1.08 billion.

Market Cap	1.11B
Enterprise Value	1.08B

Important Dates

The next estimated earnings date is Thursday, September 11, 2025.

Earnings Date	Sep 11, 2025
Ex-Dividend Date	Oct 11, 2024

Share Statistics

Current Share Class	17.40M
Shares Outstanding	n/a
Shares Change (YoY)	-0.13%
Shares Change (QoQ)	+0.09%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	17.34M

Valuation Ratios

The trailing PE ratio is 59.31 and the forward PE ratio is 44.10.

PE Ratio	59.31
Forward PE	44.10
PS Ratio	21.82
PB Ratio	16.77
P/TBV Ratio	21.58
P/FCF Ratio	65.90
P/OCF Ratio	56.91
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 42.62, with an EV/FCF ratio of 64.14.

EV / Earnings	57.73
EV / Sales	20.40
EV / EBITDA	42.62
EV / EBIT	44.57
EV / FCF	64.14

Financial Position

The company has a current ratio of 4.00, with a Debt / Equity ratio of 0.01.

Current Ratio	4.00
Quick Ratio	2.88
Debt / Equity	0.01
Debt / EBITDA	0.04
Debt / FCF	0.05
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 30.83% and return on invested capital (ROIC) is 23.68%.

Return on Equity (ROE)	30.83%
Return on Assets (ROA)	19.86%
Return on Invested Capital (ROIC)	23.68%
Return on Capital Employed (ROCE)	34.62%
Revenue Per Employee	276,943
Profits Per Employee	101,896
Employee Count	174
Asset Turnover	0.69
Inventory Turnover	0.33

Taxes

In the past 12 months, ChemoMetec has paid 5.69 million in taxes.

Income Tax	5.69M
Effective Tax Rate	23.29%

Stock Price Statistics

The stock price has increased by +46.49% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+46.49%
50-Day Moving Average	519.92
200-Day Moving Average	493.57
Relative Strength Index (RSI)	55.14
Average Volume (20 Days)	673

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ChemoMetec had revenue of GBP 50.96 million and earned 18.75 million in profits. Earnings per share was 1.08.

Revenue	50.96M
Gross Profit	46.41M
Operating Income	23.32M
Pretax Income	24.44M
Net Income	18.75M
EBITDA	24.39M
EBIT	23.32M
Earnings Per Share (EPS)	1.08

Full Income Statement

Balance Sheet

The company has 29.36 million in cash and 862,368 in debt, giving a net cash position of 28.49 million.

Cash & Cash Equivalents	29.36M
Total Debt	862,368
Net Cash	28.49M
Net Cash Per Share	n/a
Equity (Book Value)	66.31M
Book Value Per Share	3.81
Working Capital	40.83M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 19.54 million and capital expenditures -2.67 million, giving a free cash flow of 16.87 million.

Operating Cash Flow	19.54M
Capital Expenditures	-2.67M
Free Cash Flow	16.87M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 91.07%, with operating and profit margins of 45.77% and 36.79%.

Gross Margin	91.07%
Operating Margin	45.77%
Pretax Margin	47.96%
Profit Margin	36.79%
EBITDA Margin	47.87%
EBIT Margin	45.77%
FCF Margin	33.11%

Dividends & Yields

This stock pays an annual dividend of 0.45, which amounts to a dividend yield of 0.08%.

Dividend Per Share	0.45
Dividend Yield	0.08%
Dividend Growth (YoY)	-35.48%
Years of Dividend Growth	n/a
Payout Ratio	41.16%
Buyback Yield	0.13%
Shareholder Yield	0.21%
Earnings Yield	1.69%
FCF Yield	1.52%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ChemoMetec has an Altman Z-Score of 34.57 and a Piotroski F-Score of 4.

Altman Z-Score	34.57
Piotroski F-Score	4